ADC drugs approved by FDA (up to March 2022)
| Brand Name | ADC Name | Indication | Target | Linker | Payload | Company | Launch Year | |
|---|---|---|---|---|---|---|---|---|
| 1 | Mylotarg | Gemtuzumab ozogamicin (GO) | 1. Newly-diagnosed CD33+ acute myeloid leukemia 2. Relapsed or refractory CD33+ acute myeloid leukemia | CD33 | Cleavable Hydrozone linker | Calicheamicin | Pfizer | 2000 Relaunched in 2017 |
| 2 | Adcetris | Brentuximab vedotin (SGN-35) | Hodgkin lymphoma, large cell lymphoma, T-cell lymphomas | CD30 | Cleavable Valine-citrulline linker | MMAE | Seattle Genetics/ Takeda | 2011 |
| 3 | Kadcyla | Trastuzumab emtansine (T-DM1) | HER2+ breast cancer | HER2 | Noncleavable Thioether linker | DM1 | Roche | 2013 |
| 4 | Besponsa | Inotuzumab ozogamicin | Relapsed or refractory B-cell precursor acute lymphoblastic leukemia | CD22 | Cleavable Hydrozone linker | Calicheamicin | Pfizer | 2017 |
| 5 | Lumoxiti | Moxetumomab pasudotox | Relapsed or refractory hairy cell leukemia | CD22 | Fusion protein (antibody and payload) | Pseudomonas exotoxin | AstraZeneca | 2018 |
| 6 | Polivy | Polatuzumab vedotin | Relapsed or refractory diffuse large B-cell lymphoma | CD79b | Cleavable Valine-citrulline linker | MMAE | Roche | 2019 |
| 7 | Padcev | Enfortumab vedotin | Advanced or metastatic urothelial cancer | Nectin-4 | Cleavable Maleimidocaproyl valine-citrulline linker | MMAE | Seattle Genetics/ Astellas | 2019 |
| 8 | Enhertu | Fam-trastuzumab deruxtecan (DS-8201) | 1. Metastatic breast cancer 2. Locally advanced or metastatic gastric cancer | HER2 | Cleavable Maleimide tetrapeptide linker | Dxd | AstraZeneca/Daiichi Sankyo | 2019 |
| 9 | Trodelvy | Sacituzumab govitecan | 1. Locally advanced or metastatic triple-negative breast cancer 2. Locally advanced or metastatic urothelial cancer | Trop-2 | Cleavable Carbonate linker | SN-38 | Immunomedics | 2020 |
| 10 | Blenrep | Belantamab mafodotin | Relapsed or refractory multiple myeloma | BCMA | Noncleavable Maleimidocaproyl linker | MMAF | GlaxoSmithKline | 2020 |
| 11 | Zynlonta | Loncastuximab tesirine-lpyl | Relapsed or refractory large B-cell lymphoma | CD19 | Cleavable Valine-alanine linker | Pyrrolobenzodiazepine (PBD) dimer | ADC Therapeutics | 2021 |
| 12 | Tivdak | Tisotumab vedotin-tftv | Recurrent or metastatic cervical cancer | Tissue factor | Cleavable Valine-citrulline linker | MMAE | Seagen | 2021 |